172 related articles for article (PubMed ID: 21443417)
1. High incidence of independent second malignancies after non-muscle-invasive bladder cancer.
Zecha H; Schmid HP; Tschopp A; Sulser T; Engeler DS
Scand J Urol Nephrol; 2011 Sep; 45(4):245-50. PubMed ID: 21443417
[TBL] [Abstract][Full Text] [Related]
2. High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials.
Rusthoven KE; Flaig TW; Raben D; Kavanagh BD
Clin Lung Cancer; 2008 Mar; 9(2):106-11. PubMed ID: 18501097
[TBL] [Abstract][Full Text] [Related]
3. Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial?
del Rey J; Placer J; Vallmanya F; Pujol N; Prat E; Miró R; Gelabert A
BJU Int; 2010 Jul; 106(1):49-52. PubMed ID: 19922541
[TBL] [Abstract][Full Text] [Related]
4. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
[TBL] [Abstract][Full Text] [Related]
5. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
6. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
7. Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
Wu GX; Nelson RA; Kim JY; Raz DJ
Clin Lung Cancer; 2017 Sep; 18(5):543-550.e3. PubMed ID: 28412093
[TBL] [Abstract][Full Text] [Related]
8. Higher than expected association of clinical prostate and bladder cancers.
Singh A; Kinoshita Y; Rovito PM; Landas S; Silberstein J; Nsouli I; Wang CY; Haas GP
J Urol; 2005 May; 173(5):1526-9. PubMed ID: 15821472
[TBL] [Abstract][Full Text] [Related]
9. Risk of second primary malignancies in women with cervical cancer: a population-based study in Taiwan over a 30-year period.
Chen CY; Lai CH; Lee KD; Huang SH; Dai YM; Chen MC
Gynecol Oncol; 2012 Dec; 127(3):625-30. PubMed ID: 22975362
[TBL] [Abstract][Full Text] [Related]
10. Occupation and cancer - follow-up of 15 million people in five Nordic countries.
Pukkala E; Martinsen JI; Lynge E; Gunnarsdottir HK; Sparén P; Tryggvadottir L; Weiderpass E; Kjaerheim K
Acta Oncol; 2009; 48(5):646-790. PubMed ID: 19925375
[TBL] [Abstract][Full Text] [Related]
11. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991.
McCredie M; Macfarlane GJ; Bell J; Coates M
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):155-60. PubMed ID: 9138657
[TBL] [Abstract][Full Text] [Related]
12. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.
Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129
[TBL] [Abstract][Full Text] [Related]
13. The risk of bladder cancer in patients diagnosed with other primary neoplasms: analysis of the SEER database.
Anderson JK; Alanee S; Lindgren B; Slaton J
Urol Oncol; 2013 Aug; 31(6):862-5. PubMed ID: 21784673
[TBL] [Abstract][Full Text] [Related]
14. Urological implications of concurrent bladder and lung cancer.
Vainrib M; Leibovitch I
Isr Med Assoc J; 2007 Oct; 9(10):732-5. PubMed ID: 17987763
[TBL] [Abstract][Full Text] [Related]
15. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients.
Huguet J; Monllau V; Sabaté S; Rodriguez-Faba O; Algaba F; Palou J; Villavicencio H
Eur Urol; 2008 Apr; 53(4):785-92 discussion 792-3. PubMed ID: 17629611
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease.
Chen CH; Shun CT; Huang KH; Huang CY; Yu HJ; Pu YS
Urology; 2008 Jun; 71(6):1155-60. PubMed ID: 18372011
[TBL] [Abstract][Full Text] [Related]
18. New malignancies following cancer of the urinary bladder: analysis of German cancer registry data.
Lehnert M; Kraywinkel K; Pesch B; Holleczek B; Brüning T
Eur J Cancer Care (Engl); 2012 May; 21(3):398-402. PubMed ID: 22151945
[TBL] [Abstract][Full Text] [Related]
19. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer.
Chrouser K; Leibovich B; Bergstralh E; Zincke H; Blute M
J Urol; 2005 Jul; 174(1):107-10; discussion 110-1. PubMed ID: 15947588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
